Improving how HIV antibodies behave in the body across species
Official title: Improving Human Pharmacokinetic Prediction of HIV-1 Monoclonal Antibodies through Cross-Species Modeling
Funded at Fred Hutchinson Cancer Center · NIH-11469120 · Data updated 2026-11-12
A short, patient-friendly description of a project to better predict how HIV-fighting antibodies move and stay in the body, using information from multiple animal models.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 20, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $92,956 |
| NIH project number | 1R03AI203508-01 |
| Project ID | NIH-11469120 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals involved in HIV prevention or treatment research who may benefit from improved antibody therapies in the future.
✕Less likely to help
Healthy individuals or researchers not involved in HIV antibody development may not directly benefit.
What this research studies
This project aims to build a robust framework for predicting how HIV-1 monoclonal antibodies behave in humans by comparing data from different animal models. Researchers will use cross-species modeling and Bayesian methods to better estimate human pharmacokinetics and optimize dosing for future trials. The work focuses on translating preclinical findings into safer and more effective antibody treatments for people at risk of or living with HIV. It does not involve testing a treatment in people yet, but it lays the groundwork for faster, smarter clinical development of antibody-based prevention and therapy.
Why it matters
Potential benefit: If successful, the framework could improve the selection of antibody candidates and dosing strategies, potentially speeding safe access to effective HIV prevention and treatment.
How similar studies have gone: Previous cross-species pharmacokinetic modeling has shown promise, but this project seeks to strengthen and apply the approach specifically to HIV antibodies.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Huang, Yunda — Fred Hutchinson Cancer Center
- Study coordinator: Huang, Yunda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.